Browsing by Author "Aksu, Salih"

Now showing 1 - 5 of 5

Determination of burnout levels of nurses working in stem cell transplantation units in Turkey
(Wiley, 2010-12) Akkuş, Yeliz; Göker, Hakan; Aksu, Salih; Karacan, Yasemin; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.; 34869670900
Although burnout has been researched widely with regard to nurses working in different settings, until now it has not been investigated among stem cell transplantation unit nurses. This study's aim was to determine the burnout level of 57 nurses who were working in stem cell transplantation units in Turkey. The research instruments that were used included a form of demographic characteristics and the Maslach Burnout Inventory. For all the hematopoietic stem cell transplantation nurses, the mean subscale scores for emotional exhaustion were the highest, followed by personal accomplishment and then depersonalization. The burnout level rose with increasing age and duration on the job. Interventions to reduce burnout are needed at both the administrative and organizational levels. In addition, it is essential to address and prevent the problems that are related to burnout, especially among nurses who work in the same unit for a long time.
Evaluation of patients with pnh treated by eculizumab: Real world data from turkey
(Amer Soc Hematology, 2019-11-13) Karadag, Fatma Keklik; Yenerel, Mustafa Nuri; Mehmet, Yilmaz; Teke, Hava Uskudar; Özkocaman, Vildan; Tuglular, Tulin; Erdem, Fuat; Unal, Ali; Ayyildiz, Orhan; Ozet, Gulsum; Ozkan, Melda; Kaya, Emin; Ayer, Mesut; Salim, Ozan; Guvenc, Birol; Ozdogu, Hakan; Mehtap, Ozgur; Sonmez, Mehmet; Guler, Nil; Hacioglu, Sibel Kabukcu; Aydogdu, Ismet; Bektas, Ozlen; Toprak, Selami Kocak; Kaynar, Lale; Yagci, Munci; Aksu, Salih; Tombak, Anil; Karakus, Volkan; Yavasoglu, Irfan; Onec, Birgul; Ozcan, Mehmet Ali; Undar, Levent; Ali, Ridvan; Ustun, Celalettin; Ilhan, Osman; Saydam, Guray; Sahin, Fahri; ÖZKOCAMAN, VİLDAN; ALİ, RIDVAN; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Hematoloji Anabilim Dalı.; AAH-1854-2021; GXD-8209-2022
Evolution of clinical characteristics of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab in Turkey: A multicenter retrospective analysis.
(E-century Publishing Corp, 2021-01-01) Karadag, Fatma Keklik; Yenerel, Mustafa Nuri; Yilmaz, Mehmet; Uskudar, Hava; Tuglular, Tulin Firatli; Erdem, Fuat; Unal, Ali; Ayyildiz, Orhan; Ozet, Gulsum; Comert, Melda; Kaya, Emin; Ayer, Mesut; Salim, Ozan; Guvenc, Birol; Ozdogu, Hakan; Mehtap, Ozgur; Sonmez, Mehmet; Guler, Nil; Hacioglu, Sibel; Aydogdu, Ismet; Bektas, Ozlen; Toprak, Selami Kocak; Kaynar, Lale; Yagci, Munci; Aksu, Salih; Tombak, Anil; Karakus, Volkan; Yavasoglu, Irfan; Onec, Birgul; Ozcan, Mehmet Ali; Undar, Levent; Ilhan, Osman; Saydam, Guray; Sahin, Fahri; Ozkocaman, Vildan; ÖZKOCAMAN, VİLDAN; Ali, Ridvan; ALİ, RIDVAN; Bursa Uludağ Üniversitesi/Tıp Fakültesi; 0000-0003-2687-9167; 0000-0002-7798-4349; 0000-0001-8605-8497; 0000-0003-1977-0104; 0000-0002-8902-1283; 0000-0002-2176-4371; 0000-0003-0604-6475; 0000-0003-0757-9206; 0000-0001-7717-5827; 0000-0002-7195-1845; 0000-0001-9178-2850; 0000-0003-2824-1044; 0000-0001-7842-9702; AAA-2012-2021; S-4300-2019; GLU-6163-2022; HRC-6282-2023; ABH-5764-2020; W-2951-2017; ABE-4485-2021; ITT-2117-2023; IZQ-0529-2023; W-3827-2017; GLQ-6094-2022; HKM-4739-2023; ABC-8182-2021
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare X-linked genetic disorder. On the contrary to its name, it is a multisystemic disease and various symptoms other than hemoglobinuria could be occurred. It could be life threatening especially because of thromboembolic events. In the last decade, a terminal complement inhibition with eculizumab approved with promising results for PNH patients. We conducted this study to evaluate the long term experience of eculizumab therapy from Turkey for the first time. Our cohort included 138 patients with PNH treated with eculizumab between January 2008 and December 2018 at 28 centers in Turkey. Laboratory and clinical findings at the time of diagnosis and after eculizumab therapy were recorded retrospectively. The median age was 39 (range 18-84) years and median granulocyte PNH clone size was 74% (range 3.06-99.84%) at the time of diagnosis. PNH with bone marrow failure syndrome was detected in 49 patients and the rest of 89 patients had classical PNH. Overall 45 patients (32.6%) had a history of any prior thrombotic event before eculizumab therapy and only 2 thrombotic events were reported during the study period. Most common symptoms are fatigue (75.3%), hemoglobinuria (18.1%), abdominal pain (15.2%) and dysphagia (7.9%). Although PNH is commonly related with coombs negativity, we detected coombs positivity in 2.17% of patients. Seven months after the therapy, increased hemoglobin level was seen and remarkably improvement of lactate dehydrogenase level during the treatment was occurred. In addition to previous studies, our real life data support that eculizumab is well tolerated with no serious adverse events and improves the PNH related findings.
Extracorporeal photopheresis in the treatment of acute and chronic graft-versus-host disease: A position statement from the Turkish Society of Apheresis (TSA)
(Elsevier, 2022-02-01) Kaynar, Leylagül; Tekgündüz, Emre; Kozanoğlu, İlknur; Özkan, Hasan Atilla; Aksu, Salih; Özkalemkaş, Fahir; Demirkan, Fatih; ÖZKALEMKAŞ, FAHİR; Bursa Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı/Hematoloji Anabilim Dalı; DLR-8474-2022
Graft versus host disease (GVHD) is still the most important cause of mortality and morbidity after allogeneic stem cell transplantation. Though perfect response rates are not achieved, steroids are still the first-line treat-ment. In the face of the presence of the drugs approved by FDA in recent years for acute and chronic GVHD as second-line therapy in the steroid-refractory group, there exists no standard approach. Extracorporeal photopheresis (ECP) with an immunomodulatory effect, is favored in the treatment of both acute and chronic steroid refractory GVHD as it does not increase the risk of relapses or infections. Having a low profile of side effects, ECP is also generally well-tolerated by patients. Being a time requiring procedure, the fact is that it is not able to be practiced in all health centers and requires central venous catheters in patients unfit for venous access may be enumerated among its shortcomings. No complete standard is available with respect to ECP application frequency-time; it varies from one center to another. The Turkish Society of Apheresis established the Turkish ECP (TECP) group and sought some answers to the questions regarding the use of ECP in the treatment of GVHD, and issued a position statement.
Kök hücre nakli hastalarında tamamlayıcı ve alternatif tedavi kullanımı
(Uludağ Üniversitesi, 2011-12-16) Akkuş, Yeliz; Akdemir, Nuran; Göker, Hakan; Aksu, Salih; Sucak, Gülsan A.; Özet, Gülsüm; İlhan, Osman; Karacan, Yasemin; Tekinalp, Atakan; Özkocaman, Vildan; Ali, Rıdvan; Özkalemkaş, Fahir; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı/Hematoloji Bilim Dalı.
Bu çalışma kök hücre nakli yapılan hastaların nakil öncesi ya da nakil sonrası TAT uygulamalarının değerlendirilmesi amacıyla tanımlayıcı olarak yapılmıştır. Veriler Ankara’da bulunan 5 hastanede tedavi gören 153 hastadan toplanmıştır. Veri toplama formu sosyo-demografik özellikler ve geçen ve bir önceki yıllardaki ilik nakillerinde TAT kullanımına ilişkin bilgileri kapsamaktadır. Hastaların TAT rak %48.4’ünün şifalı bitkisel ürünleri, %28.1’inin dini aktiviteleri (dualar) kullandığı belirlenmiştir. Hastaların sıklıkla bitkisel ürün olarak ısırgan otunu (%69.0) ,hayvansal ürün olarak ise kaplumbağa kanını kullandığı saptandı. Hastalar çoğunlukla tedavi edici, gevşetici ve manevi güç olarak TAT kullandığını belirtmiştir. Hastaların %79.0’u doktorları ile TAT kullanımlarına ilişkin tartışmadıklarını/danışmadıklarını belirtmiştir. Bu çalışmanın bulgularının diğer çalışmalardakilerle benzer olduğu saptanmıştır.